Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 9Stomach Neoplasms 5Endometrial Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Adenocarcinoma 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Melanoma 1

Interventions

Gemcitabine 26Specimen Handling 20130-nm albumin-bound paclitaxel 18Magnetic Resonance Spectroscopy 13Irinotecan 13Biopsy 12Fluorouracil 11Leucovorin 10Oxaliplatin 9Cyclophosphamide 8pembrolizumab 7fludarabine 7Albumin-Bound Paclitaxel 7Cisplatin 6Cetuximab 6Nivolumab 5durvalumab 4Taxes 4Radiosurgery 4Pemetrexed 4Capecitabine 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3dehydroftorafur 3aldesleukin 3Radiotherapy 3Immunoglobulin G 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × trastuzumab deruxtecan × 30 days × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡